Disruption of glutamate-glutamine-GABA cycle significantly impacts on suicidal behaviour: Survey of the literature and own findings on glutamine synthetase

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 7, 2013, Pages 900-913

  Bernstein, Hans Gert ^a   Tausch, Anne ^a   Wagner, Rebecca ^a   Steiner, Johann ^a   Seeleke, Patrick ^a   Walter, Martin ^a   Dobrowolny, Henrik ^a   Bogerts, Bernhard ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gamma aminobutyric acid; Glutamate; Glutamine; Glutamine synthetase; Human brain; Immunohistochemistry; Suicide

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; CITALOPRAM; EXCITATORY AMINO ACID TRANSPORTER; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DECARBOXYLASE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLUTAMINASE; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PARVALBUMIN;

ADRENERGIC TRANSMISSION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC ANALYSIS; GLIA CELL; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROSCOPY; MORPHOMETRICS; PREFRONTAL CORTEX; PROTEIN EXPRESSION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED INTERVIEW; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYNAPTIC TRANSMISSION; THALAMUS DORSOMEDIAL NUCLEUS;

BRAIN; CASE-CONTROL STUDIES; CELL COUNT; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE-AMMONIA LIGASE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MALE; MIDDLE AGED; NEUROGLIA; SCHIZOPHRENIA; SUICIDE; SYNAPTIC TRANSMISSION;

EID: 84889011079     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990091     Document Type: Article

References (113)

1. Nock, M. K.; Borges, G.; Bromet, E.J.; Cha, C.B.; Kessler, R.C; Lee, S. Suicide and suicidal behavior. Epidemiol. Rev., 2008, 30, 133-154.
2. Van Heeringen, K. The neurobiology of suicide and suicidality. Can. J. Psychiatry, 2003, 48, 292-300.
3. Eid, T.; Behar, K.; Dhaher, R.; Bumanglag, A.V.; Lee, T.S. Roles of glutamine synthetase inhibition in epilepsy. Neurochem. Res., 2012, 37, 2339-2350.
4. Bernstein, H.G.; Steiner, J.; Bogerts, B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev. Neurother., 2009, 9, 1059-1071.
5. Kam, K.; Nicoll, R. Excitatory synaptic transmission persists independently of the glutamate-glutamine cycle. J. Neurosci., 2007, 27, 9192-9200.
6. Martinez-Hernandez, A.; Bell, K.P.; Norenberg M.D. Glutamine synthetase: glial localization in brain. Science, 1977, 195(4284), 1356-1358.
7. Albrecht, J.; Sidoryk-Wgrzynowicz, M.; Zieli ska, M.; Aschner, M. Roles of glutamine in neurotransmission. Neuron Glia Biol., 2010, 6, 263-276.
8. Yildiz-Yesiloglu, A.; Ankerst, D.P. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res., 2006, 147, 1-25.
9. Hasler, G.; van der Veen, J.W.; Tumonis, T.; Meyers, N.; Shen, J.; Drevets, W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry, 2007, 64, 93-200.
10. Yüksel, C.; Öngür, D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry, 2010, 68, 85-94.
11. Sanacora, G.; Gueorguieva, R; Epperson, C.N.; Wu, Y.T.; Appel, M.; Rothman, D.L; Krystal, J.H.; Mason, G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry, 2004, 61, 705-713.
12. Salvadore, G.; van der Veen, J.W.; Zhang, Y.; Marenco, S.; Machado-Vieira, R.; Baumann, J.; Ibrahim, L.A.; Luckenbaugh, D.A.; Shen, J.; Drevets, W.C.; Zarate, C.A. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int. J. Neuropsychopharmacol. 2012, 5(8), 1063-1072.
13. Grimm, S.; Luborzewski, A.; Schubert, F.; Merkl, A.; Kronenberg, G.; Colla, M.; Heuser, I.; Bajbouj, M. Region-specific glutamate changes in patients with unipolar depression. J. Psychiatr. Res., 2012, 46, 1059-1065.
14. Luykx, J.J.; Laban, K.G.; van den Heuvel, M.P.; Boks, M.P.; Mandl, R.C.; Kahn, R.S.; Bakker, S.C. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings Neurosci. Biobehav. Rev., 2012, 36, 198-205.
15. Price, R.B.; Shungu, D.C.; Mao, X.; Nestadt, P.; Kelly, C.; Collins, K.A.; Murrough, J.W.; Charney, D.S.; Mathew, S.J. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol. Psychiatry, 2009, 65, 792-800.
16. Gabbay, V.; Mao, X.; Klein, R.G.; Ely, B.A.; Babb, J.S.; Panzer, A.M.; Alonso, C.M.; Shungu, D.C. Anterior cingulate cortex -aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch. Gen. Psychiatry, 2012, 69, 139-149.
17. Gigante, A.D.; Bond, D.J.; Lafer, B.; Lam, R.W.; Young, L.T.; Yatham, L.N. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord., 2012, 14, 478-487.
18. Michael, N.; Erfurth, A.; Ohrmann, P.; Gössling, M.; Arolt, V.; Heindel, W.; Pfleiderer B. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology, 2003, 168, 344-346.
19. Moore, C.M.; Frazier, J.A.; Glod, C.A.; Breeze, J.L; Dieterich, M.; Finn, C.T.; Frederick, B.; Renshaw, P.F. Glutamine and glutamate levels in children and adolescents with bipolar disorder: a 4.0-T proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J. Am. Acad. Child Adolesc. Psychiatry, 2007, 46, 524-534.
20. Kaufman, R.E.; Ostacher, M.J.; Marks, E.H.; Simon, N.M.; Sachs, G.S.; Jensen, J.E.; Renshaw, P.F.; Pollack, M.H. Brain GABA levels in patients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 427-434.
21. Olbrich, H.M.; Valerius, G.; Rüsch, N.; Buchert, M.; Thiel, T.; Hennig, J.; Ebert, D.; Van Elst, L.T. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J. Biol. Psychiatry, 2008, 9, 59-63.
22. Théberge, J.; Bartha, R.; Drost, D.J.; Menon, R.S.; Malla, A.; Takhar, J.; Neufeld, R.W.; Rogers, J.; Pavlosky, W.; Schaefer, B.; Densmore, M.; Al-Semaan, Y.; Williamson, P.C. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry, 2002, 159, 1944-1946.
23. Maddock, R.J.; Buonocore, M.H. MR Spectroscopic studies of the brain in psychiatric disorders. Curr. Top. Behav. Neurosci., 2012, 11, 199-251.
24. Egerton, A.; Brugger, S.; Raffin, M.; Barker, G.J.; Lythgoe, D.J.; McGuire, P.K.; Stone, J.M. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology, 2012, 37(11), 2515-2521.
25. Kegeles, L.S.; Mao, X; Stanford, A.D.; Girgis, R.; Ojeil, N.; Xu, X.; Gil, R.; Slifstein, M.; Abi-Dargham, A.; Lisanby, S.H.; Shungu, D.C. Elevated prefrontal cortex -aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry, 2012, 69, 449-459.
26. Hoerst, M.; Weber-Fahr, W.; Tunc-Skarka, N.; Ruf, M.; Bohus, M.; Schmahl, C.; Ende, G. Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch. Gen. Psychiatry, 2010, 67, 946-954.
27. Hashimoto, K.; Sawa, A.; Iyo, M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry, 2007, 62, 1310-1306.
28. Korpi, E.R.; Kleinman, J.E.; Goodman, S.I.; Wyatt, R.J. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Res., 1987, 22, 291-301.
29. Yang, J.; Shen, J. Elevated endogenous GABA concentration attenuates glutamate-glutamine cycling between neurons and astroglia. J. Neural Transm., 2009, 116, 291-300.
30. Schwarz, E.; Guest, P.C.; Steiner, J.; Bogerts, B.; Bahn, S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl. Psychiatry, 2012, 2, e82.
31. Vasic, N.; Connemann, B.J.; Wolf, R.C.; Tumani, H.; Brettschneider, J. Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? Eur. Arch. Psychiatry Clin. Neurosci., 2011, 262(5), 375-391.
32. Garakani, A.; Martinez, J.M.; Yehuda, R.; Gorman, J.M. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. J. Affect. Disord. 2012, 146(2), 262-265.
33. Lee, R.; Petty, F.; Coccaro, E.F. Cerebrospinal fluid GABA concentration: relationship with impulsivity and history of suicidal behavior, but not aggression, in human subjects. J. Psychiatr. Res. 2009, 43, 353-359.
34. Berrettini, W.H.; Nurnberger, J.I., Jr.; Narrow, W.; Simmons-Alling, S.; Gershon, E.S. Cerebrospinal fluid studies of bipolar patients with and without a history of suicide attempts. Ann. NY Acad. Sci., 1986, 487, 97-201.
35. Roy, A. Neuropeptides in relation to suicidal behavior in depression. Neuropsychobiology, 1993, 28, 184-186.
36. Daniele, S.; Da Pozzo, E.; Abelli, M.; Panighini, A.; Pini, S.; Gesi, C.; Lari, L.; Cardini, A.; Cassano, G.B.; Martini, C. Platelet uptake of GABA and glutamate in patients with bipolar disorder. Bipolar Disord., 2012, 14, 301-308.
37. Arrúe, A.; Dávila, R.; Zumárraga, M.; Basterreche, N.; González-Torres, M.A.; Goienetxea, B.; Zamalloa, M.I.; Anguiano, J.B.; Guimón, J. GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients. Neurochem. Res., 2010, 35, 247-253.
38. He, Y.; Yu, Z.; Giegling, I; Xie, L.; Hartmann, A.M.; Prehn, C.; Adamski, J.; Kahn, R.; Li, Y.; Illig, T.; Wang-Sattler, R.; Rujescu, D. Schizophrenia shows a unique metabolomics signature in plasma. Transl. Psychiatry, 2012, 2, e149.
39. Kim, S; Choi, K.H; Baykiz, A.F.; Gershenfeld, H.K. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genomics, 2007, 8, 413.
40. Boksha, I.S.; Tereshkina, E.B.; Burbaeva, G.S. Glutamine synthetase and glutamine synthetase-like protein from human brain: purification and comparative characterization. J. Neurochem., 2000, 75, 2574-2582.
41. Choudary, P.V.; Molnar, M.; Evans, S.J.; Tomita, H.; Li, J.Z.; Vawter, M.P.; Myers, R.M; Bunney, W.E., Jr.; Akil, H.; Watson, S.J.; Jones, E.G. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. USA, 2005, 102, 15653-15658.
42. Beasley, C.L; Pennington, K.; Behan, A.; Wait, R.; Dunn, M.J.; Cotter, D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics, 2006, 6(11), 3414-3425.
43. Sequeira, A.; Mamdani, F.; Ernst, C.; Vawter, M.P.; Bunney, W.E.; Lebel, V.; Rehal, S.; Klempan, T.; Gratton, A.; Benkelfat, C.; Rouleau, G.A.; Mechawar, N.; Turecki, G. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One, 2009, 4, e6585.
44. Zhang, B.; Yuan, Y.; Jia, Y.; Yu, X.; Xu, Q.; Shen, Y.; Shen, Y. An association study between polymorphisms in five genes in glutamate and GABA pathway and paranoid schizophrenia. Eur. Psychiatry, 2005, 20, 45-49.
45. Burbaeva, G.Sh.; Boksha, I.S.; Turishcheva, M.S.; Vorobyeva, E.A.; Savushkina, O.K.; Tereshkina, E.B. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003 27, 675-680.
46. Burbaeva, G.Sh.; Boksha, I.S; Tereshkina, E.B.; Savushkina, O.K.; Starodubtseva, L.I.; Turishcheva, M.S; Mukaetova-Ladinska, E. Systemic neurochemical alterations in schizophrenic brain: glutamate metabolism in focus. Neurochem. Res., 2007, 32, 1434-1444.
47. Steffek, A.E.; McCullumsmith, R.E.; Haroutunian, V.; Meador-Woodruff, J.H. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr. Res., 2008, 103, 71-82.
48. Katsel, P.; Byne, W.; Roussos, P.; Tan, W.; Siver, L.; Haroutunian, V. Astrocyte and glutamate markers in the superficial deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology, 2011, 36, 1171-1177.
49. Bruneau, E.G.; McCullumsmith, R.E.; Haroutunian, V.; Davis, K.L; Meador-Woodruff, J.H. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr. Res., 2005, 75, 27-34.
50. Martins-de-Souza, D.; Schmitt, A.; Röder, R.; Lebar, M.; Schneider-Axmann, T.; Falkai, P.; Turck, C.W. Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. J. Psychiatr. Res., 2010, 44, 989-991.
51. Toro, C.T; Hallak, J.E.; Dunham, J.S.; Deakin, J.F. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci. Lett., 2006, 404, 276-281.
52. Kalkman, H.O. Circumstantial evidence for a role of glutamine-synthetase in suicide. Med. Hypotheses, 2011, 76, 905-907.
53. Burbaeva, G.Sh.; Boksha, I.S; Kaleda, V.G.; Barkhatova, A.N.; Turishcheva, M.S.; Omel'chenko, M.A; Tereshkina, E.B.; Savushkina, O.K.; Starodubtseva, L.I.; Prokhorova, T.A.; Vorob'eva, E.A. Glutamine synthetase-like protein, glutamate dehydrogenase, and cytochrome c-oxidase in platelets of patients with the first episode psychosis in the course of treatment. Zh. Nevrol. Psikhiatr. Im. SS Korsakova, 2011, 111, 61-66.
54. Maeshima, H.; Ohnuma, T.; Sakai, Y.; Shibata, N.; Baba, H.; Ihara, H.; Higashi, M.; Ohkubo, T.; Nozawa, E.; Abe, S.; Ichikawa, A.; Nakano, Y.; Utsumi, Y.; Suzuki, T.; Arai, H. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 1410-1418.
55. Gluck, M.R.; Thomas, R.G; Davis, K.L; Haroutunian, V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am. J. Psychiatry, 2002, 159, 1165-1173.
56. Schreiber, S.; Bernstein, H.G.; Fendrich, R.; Stauch, R.; Ketzler, B.; Dobrowolny, H.; Steiner, J.; Schreiber, F.; Bogerts, B. Increased density of GAD65/67 immunoreactive neurons in the posterior subiculum and parahippocampal gyrus in treated patients with chronic schizophrenia. World J. Biol. Psychiatry, 2011, 12, 57-65.
57. Sibille, E.; Morris, H.M.; Kota, R.S.; Lewis, D.A. GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int. J. Neuropsychopharmacol., 2011, 14, 21-34.
58. Rajkowska, G.; O'Dwyer, G.; Teleki, Z.; Stockmeier, C.A.; Miguel-Hidalgo, J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology, 2007, 32, 471-482.
59. Thompson, R.M.; Weickert, C.S.; Wyatt, E.; Webster, M.J. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci., 2011, 36, 195-203.
60. Gos, T.; Steiner, J.; Bielau, H.; Dobrowolny, H.; Günther, K.; Mawrin, C.; Krzy anowski, M.; Hauser, R.; Brisch, R.; Bernstein, H.G.; Jankowski, Z.; Braun, K.; Bogerts, B. Differences between unipolar and bipolar I depression in the quantitative analysis of glutamic acid decarboxylase-immunoreactive neuropil. Eur. Arch. Psychiatry Clin. Neurosci., 2012, 262(8), 647-655.
61. Cheetham, S.C.; Crompton, M.R.; Katona, C.L.; Parker, S.J.; Horton, R.W. Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res., 1988, 460, 114-123.
62. Bielau, H.; Steiner, J.; Mawrin, C.; Trübner, K.; Brisch, R.; Meyer-Lotz, G.; Brodhun, M.; Dobrowolny, H.; Baumann, B.; Gos, T.; Bernstein, H.G.; Bogerts, B. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann. NY Acad. Sci., 2007, 1096, 157-169.
63. Gos, T.; Günther, K.; Bielau, H.; Dobrowolny, H.; Mawrin, C.; Trübner, K.; Brisch, R.; Steiner, J.; Bernstein, H.G.; Jankowski, Z.; Bogerts, B. Suicide and depression in the quantitative analysis of glutamic acid decarboxylase-Immunoreactive neuropil. J. Affect. Disord., 2009, 113, 45-55.
64. De Luca, V.; Muglia, P.; Masellis, M.; Jane Dalton, E.; Wong, G.W.: Kennedy, J.L. Polymorphisms in glutamate decarboxylase genes: analysis in schizophrenia. Psychiatr. Genet., 2004, 14, 39-42.
65. Watis, L.; Chen, S.H.; Chua, H.C.; Chong, S.S.; Sim, K. Glutamatergic abnormalities of the thalamus in schizophrenia. J. Neural Transm., 2008, 115, 493-511.
66. Holemans, S.; De Paermentier, F.; Horton, R.W.; Crompton, M.R.; Katona, C.L.; Maloteaux, J.M. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res., 1993, 616, 138-143.
67. Nowak, G.; Szewczyk, B.; Sadlik, K.; Piekoszewski, W.; Trela, F.; Florek, E.; Pilc, A. Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Pol. J. Pharmacol., 2003, 55, 455-459.
68. Nowak, G.; Ordway, G.A.; Paul, I.A. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res., 1995, 675, 157-164.
69. Palmer, A.M.; Burns, M.A.; Arango, V.; Mann, J.J. Similar effects of glycine, zinc and an oxidizing agent on [3H]dizocilpine binding to the N-methyl-D-aspartate receptor in neocortical tissue from suicide victims and controls. J. Neural Transm. Gen. Sect., 1994, 96, 1-8.
70. Nudmamud-Thanoi, S.; Reynolds, G.P. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci. Lett., 2004, 372, 173-177.
71. Sokolowski, M.; Ben-Efraim, Y.J.; Wasserman, J.; Wasserman, D. Glutamatergic GRIN2B and polyaminergic ODC1 genes in suicide attempts: associations and gene-environment interactions with childhood/adolscent physical assault. Mol. Psychiatry, 2012 in press; doi: 10.1038/mp.2012.112.
72. Klempan, T.A.; Sequeira, A.; Canetti, L.; Lalovic, A.; Ernst, C.; ffrench-Mullen J.; Turecki. G. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol. Psychiatry, 2009, 14, 175-189.
73. Noga, J.T.; Hyde, T.M.; Herman, M.M.; Spurney, C.F.; Bigelow, L.B.; Weinberger, D.R.; Kleinman, J.E. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse, 1997, 27, 168-176.
74. Freed, W.J.; Dillon-Carter, O.; Kleinman, J.E. Properties of [3H]AMPA binding in postmortem human brain from psychotic subjects and controls: increases in caudate nucleus associated with suicide. Exp. Neurol., 1993, 121, 48-56.
75. Noga, J.T.; Wang, H. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse, 2002, 45, 250-258.
76. Lyddon, R.; Navarrett, S.; Dracheva, S. Ionotropic glutamate receptor mRNA editing in the prefrontal cortex: no alterations in schizophrenia or bipolar disorder. J. Psychiatry Neurosci., 2012, 37, 267-272.
77. Laje, G.; Paddock, S.; Manji, H.; Rush, A.J.; Wilson, A.F.; Charney, D.; McMahon, F.J. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am. J. Psychiatry, 2007, 164, 1530-1538.
78. Fiori, L.M.; Turecki. G. Broadening our horizons: gene expression profiling to help better understand the neurobiology of suicide and depression. Neurobiol. Dis., 2012, 45, 14-22.
79. Altar, C.A.; Vawter, M.P.; Ginsberg, S.D. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology, 2009, 133, 13-24.
80. Desmyter, S.; van Heeringen, C.; Audenaert, K. Structural and functional neuroimaging studies of the suicidal brain. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35, 796-808.
81. Fernández-Navarro, P.; Vaquero-Lorenzo, C.; Blasco-Fontecilla, H.; Díaz-Hernández, M.; Gratacòs, M.; Estivill, X.; Costas, J.; Carracedo, A.; Fernández-Piqueras, J.; Saiz-Ruiz J.; Baca-Garcia, E. Genetic epistasis in female suicide attempters. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 38, 294-301.
82. Baca-Garcia, E.; Vaquero, C.; Diaz-Sastre, C.; Jimenez-Treviño, L.; Saiz-Ruiz, J.; Fernández-Piqueras, J.; de Leon, J. Lack of association between polymorphic variations in the alpha 3 subunit GABA receptor gene (GABRA3) and suicide attempts. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28, 409-412.
83. Sequeira, A.; Klempan, T.; Canetti, L.; Ffrench-Mullen, J.; Benkelfat, C.; Rouleau, G.A.; Turecki, G. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol. Psychiatry, 2007, 12, 640-655.
84. Merali, Z.; Du, L.; Hrdina, P.; Pal kovits, M.; Faludi, G.; Poulter, M.O.; Anisman, H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci., 2004, 24, 1478-1485.
85. Poulter, M.O.; Du, L.; Zhurov, V.; Palkovits, M.; Faludi, G.; Merali, Z.; Anisman, H. Altered organization of GABA(A) receptor mRNA expression in the depressed suicide brain. Front. Mol. Neurosci., 2010, 29, 33.
86. Poulter, M.O.; Du, L.; Weaver, I.C.; Palkovits, M.; Faludi, G.; Merali, Z.; Szyf, M.; Anisman, H. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol. Psychiatry, 2008, 64, 645-652.
87. Zhu, H.; Karolewicz, B., Nail, E.; Stockmeier, C.A.; Szebeni, K.; Ordway, G.A. Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide. Brain Res., 2006, 1125, 138-146.
88. Marazziti, D.; Dell'Osso, B.; Baroni, S.; Masala, I.; Di Nasso, E.; Giannaccini, G.; Conti, L. Decreased density of peripheral benzodiazepine receptors in psychiatric patients after a suicide attempt. Life Sci., 2005, 77, 3268-3275.
89. Soreni, N., Apter, A.; Weizman, A.; Don-Tufeled, O.; Leschiner, S.; Karp, L.; Gavish, M. Decreased platelet peripheral-type benzodiazepine receptors in adolescent inpatients with repeated suicide attempts. Biol. Psychiatry, 1999, 46, 484-488.
90. Rochet, T; Kopp, N.; Vedrinne, J.; Deluermoz, S.; Debilly, G.; Miachon, S. Benzodiazepine binding sites and their modulators in hippocampus of violent suicide victims. Biol. Psychiatry, 1992, 32, 922-931.
91. Pandey, G.N.; Conley, R.R.; Pandey, S.C.; Goel, S.; Roberts, R.C.; Tamminga, C.A.; Chute, D.; Smialek, J. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Res., 1997, 71, 137-149.
92. Cross, J.A.; Cheetham, S.C.; Crompton, M.R.; Katona, C.L.; Horton, R.W. Brain GABAB binding sites in depressed suicide victims. Psychiatry Res., 1988, 26, 119-129.
93. Arranz, B.; Cowburn, R.; Eriksson, A.; Vestling, M.; Marcusson, J. Gamma-aminobutyric acid-B (GABAB) binding sites in postmortem suicide brains. Neuropsychobiology, 1992, 26(1-2), 33-36.
94. González-Maeso, J.; Rodríguez-Puertas, R.; Meana, J.J.; García-Sevilla, J.A.; Guimón, J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol. Psychiatry, 2002, 7, 755-767.
95. Choudhury, P.R.; Lahiri, S.; Rajamma, U. Glutamate mediated signaling in the pathophysiology of autism spectrum disorders. Pharmacol. Biochem. Behav., 2012 100, 841-849.
96. Murphy, T.M.; Ryan, M.; Foster, T.; Kelly, C.; McClelland, R.; O'Grady, J.; Corcoran, E.; Brady, J.; Reilly, M.; Jeffers, A.; Brown, K.; Maher, A.; Bannan, N.; Casement, A.; Lynch, D.; Bolger, S.; Tewari, P.; Buckley, A.; Quinlivan, L.; Daly, L.; Kelleher, C.; Malone, K.M. Risk and protective genetic variants in suicidal behaviour: association with SLC1A2, SLC1A3, 5-HTR1B &NTRK2 polymorphisms. Behav. Brain Funct., 2011, 7, 22.
97. Ernst, C.; Dumoulin, P.; Cabot, S.; Erickson, J.; Turecki, G. SNAT1 and a family with high rates of suicidal behavior. Neuroscience, 2009, 162, 415-422.
98. Sundman-Eriksson, I.; Allard, P. [(3)H]Tiagabine binding to GABA transporter-1 (GAT-1) in suicidal depression. J. Affect. Disord., 2002, 71, 29-33.
99. Gould, T.D.; Can, A.; Gottesman, I.I.; Courtet, P. Differential lithium efficacy in reducing suicidal behaviors compared with suicidal thoughts. Am. J. Psychiatry, 2012, 169, 98-99.
100. Marcus, S.R.; Nadiger, H.A.; Chandrakala, M.V.; Rao, T.I.; Sadasivudu, B. Acute and short-term effects of lithium on glutamate metabolism in the rat brain Biochem. Pharmacol., 1986, 35, 365-369.
101. Keilhoff, G.; Becker, A.; Grecksch, G.; Wolf, G.; Bernstein, H.G. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience, 2004, 126, 591-598.
102. Zarate, C.A., Jr.; Brutsche, N.E.; Ibrahim, L.; Franco-Chaves, J.; Diazgranados, N.; Cravchik, A.; Selter, J.; Marquardt, C.A.; Liberty, V.; Luckenbaugh, D.A. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry, 2012, 71, 939-946.
103. Gottmann, K.; Mittmann, T.; Lessmann, V. BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Exp. Brain Res., 2009, 199(3-4), 203-234.
104. Sher, L. Brain-derived neurotrophic factor and suicidal behavior. QLM, 2011, 104, 455-458.
105. Hercher, C.; Turecki, G.; Mechawar, N. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J. Psychiatr. Res., 2009, 43, 947-961.
106. Bernstein, H.G.; Sahin, J.; Smalla, K.H.; Gundelfinger, E.D.; Bogerts, B.; Kreutz, M.R. A reduced number of cortical neurons show increased caldendrin protein levels in chronic schizophrenia. Schizophr. Res., 2007, 96, 246-256.
107. Danos, P.; Baumann, B.; Bernstein, H.G.; Franz, M.; Stauch, R.; Northoff, G.; Krell, D.; Falkai, P.; Bogerts. B. Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res., 1998, 82, 1-10.
108. Mai, J.K.; Assheuer, J.; Paxinos, G. Atlas of the Human Brain. Academic Press, New York, 1997.
109. Bernstein, H.G.; Baumann, B.; Danos, P.; Diekmann, S.; Bogerts, B.; Gundelfinger, E.D.; Braunewell, K.H. Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brain. J. Neurocytol., 1999, 28, 655-662.
110. Bernstein, H.G.; Stanarius, A.; Baumann, B.; Henning, H.; Krell, D.; Danos, P.; Falkai, P.; Bogerts, B. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience, 1998, 83, 867-875.
111. Danos, P.; Schmidt, A.; Baumann, B., Bernstein, H.G.; Northoff, G.; Stauch, R.; Krell, D.; Bogerts, B. Volume and neuron number of the mediodorsal thalamic nucleus in schizophrenia: a replication study. Psychiatry Res., 2005, 140, 281-289.
112. Zielke, H.R.; Jackson, M.J.; Tildon, J.T.; Max, S.R. A glutamatergic mechanism for aluminum toxicity in astrocytes. Mol. Chem. Neuropathol., 1993, 19, 219-233.
113. Bernstein, H.G.; Smalla, K.H; Dürrschmidt, D.; Keilhoff, G.; Dobrowolny, H.; Steiner, J.; Schmitt, A.; Kreutz, M.R.; Bogerts, B. Increased density of prohibitin-immunoreactive oligodendrocytes in the dorsolateral prefrontal white matter of subjects with schizophrenia suggests extra neuronal roles for the protein in the disease. Neuromol. Med., 2012, 14, 270-280.